The Fukuoka Kidney disease Registry (FKR) Study: design and methods

作者：Tanaka Shigeru; Ninomiya Toshiharu; Fujisaki Kiichiro; Yoshida Hisako; Nagata Masaharu; Masutani Kosuke; Tokumoto Masanori; Mitsuiki Koji; Hirakata Hideki; Fujimi Satoru; Kiyohara Yutaka; Kitazono Takanari; Tsuruya Kazuhiko

来源：Clinical and Experimental Nephrology, 2017, 21(3): 465-473.

DOI：10.1007/s10157-016-1294-4

• Biomarkers
• Epidemiology
• Omics
• Proteinuria
• Renal replacement therapy

Chronic kidney disease (CKD) is an established independent risk factor for progression to end-stage renal disease (ESRD) and incidence of cardiovascular disease (CVD). The onset and progression of CKD are associated with both genetic predisposition and various lifestyle-related factors, but little is known about the influence of genetic-environmental interactions on the incidence of ESRD or CVD in patients with CKD.
The Fukuoka Kidney disease Registry (FKR) Study is designed as one of the largest prospective, multicenter, observational cohort studies in non-dialysis dependent CKD patients. The FKR Study aims to enroll approximately 5000 individuals at multiple clinical centers and follow them for up to at least 5 years. At baseline, subjects enrolled in the FKR Study will fill out extensive lifestyle-related questionnaires. Further, their health status and treatments will be monitored annually through a research network of nephrology centers. Blood and urine samples, including DNA/RNA, will be collected at the time of enrolment and every 5-years follow-up.
The FKR Study will provide many insights into the onset and progression of CKD, which will suggest hypothesis-driven interventional clinical trials aimed at reducing the burden of CKD. The features of the FKR Study may also facilitate innovative research to identify and validate novel risk factors, including genetic susceptibility and biomarkers, using biomaterials by high-throughput omics technologies.

• 出版日期2017-6